Merryn Voysey1, Dominic F Kelly2, Thomas R Fanshawe3, Manish Sadarangani4, Katherine L O'Brien5, Rafael Perera3, Andrew J Pollard2. 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England2Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, England3National Institute for Health Research Oxford Biomedical Research Centre, Oxford, England. 2. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, England3National Institute for Health Research Oxford Biomedical Research Centre, Oxford, England. 3. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England. 4. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, England3National Institute for Health Research Oxford Biomedical Research Centre, Oxford, England4Vaccine Evaluation Center, British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada. 5. International Vaccine Access Centre, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
Importance: The design of infant immunization schedules requires an understanding of the factors that determine the immune response to each vaccine antigen. Data Sources: Deidentified individual participant data from GlaxoSmithKline clinical trials were obtained through Clinical Study Data Request. The data were requested on January 2, 2015, and final data were received on April 11, 2016. Study Selection: Immunogenicity trials of licensed or unlicensed vaccines administered to infants were included if antibody concentrations in infants were measured prior to the first dose of vaccine. Data Extraction and Synthesis: The database was examined; studies that appeared to have appropriate data were reviewed. Main Outcomes and Measures: Antigen-specific antibody concentration measured 1 month after priming vaccine doses, before booster vaccination, and 1 month after booster vaccine doses. Results: A total of 7630 infants from 32 studies in 17 countries were included. Mean (SD) age at baseline was 9.0 (2.3) weeks; 3906 (51.2%) were boys. Preexisting maternal antibody inhibited infant antibody responses to priming doses for 20 of 21 antigens. The largest effects were observed for inactivated polio vaccine, where 2-fold higher maternal antibody concentrations resulted in 20% to 28% lower postvaccination antibody concentration (geometric mean ratios [GMRs], type 1: 0.80; 95% CI, 0.78-0.83; type 2: 0.72; 95% CI, 0.69-0.74; type 3: 0.78; 95% CI, 0.75-0.82). For acellular pertussis antigens, 2-fold higher maternal antibody was associated with 11% lower postvaccination antibody for pertussis toxoid (GMR, 0.89; 95% CI, 0.87-0.90) and filamentous hemagglutinin (GMR, 0.89; 95% CI, 0.88-0.90) and 22% lower pertactin antibody (GMR, 0.78; 95% CI, 0.77-0.80). For tetanus and diphtheria, these estimates were 13% (GMR, 0.87; 95% CI, 0.86-0.88) and 24% (GMR, 0.76; 95% CI, 0.74-0.77), respectively. The influence of maternal antibody was still evident in reduced responses to booster doses of acellular pertussis, inactivated polio, and diphtheria vaccines at 12 to 24 months of age. Children who were older when first immunized had higher antibody responses to priming doses for 18 of 21 antigens, after adjusting for the effect of maternal antibody concentrations. The largest effect was seen for polyribosylribitol phosphate antibody, where responses were 71% higher per month (GMR, 1.71; 95% CI, 1.52-1.92). Conclusions and Relevance: Maternal antibody concentrations and infant age at first vaccination both influence infant vaccine responses. These effects are seen for almost all vaccines contained in global immunization programs and influence immune response for some vaccines even at the age of 24 months. These data highlight the potential for maternal immunization strategies to influence established infant programs.
Importance: The design of infant immunization schedules requires an understanding of the factors that determine the immune response to each vaccine antigen. Data Sources: Deidentified individual participant data from GlaxoSmithKline clinical trials were obtained through Clinical Study Data Request. The data were requested on January 2, 2015, and final data were received on April 11, 2016. Study Selection: Immunogenicity trials of licensed or unlicensed vaccines administered to infants were included if antibody concentrations in infants were measured prior to the first dose of vaccine. Data Extraction and Synthesis: The database was examined; studies that appeared to have appropriate data were reviewed. Main Outcomes and Measures: Antigen-specific antibody concentration measured 1 month after priming vaccine doses, before booster vaccination, and 1 month after booster vaccine doses. Results: A total of 7630 infants from 32 studies in 17 countries were included. Mean (SD) age at baseline was 9.0 (2.3) weeks; 3906 (51.2%) were boys. Preexisting maternal antibody inhibited infant antibody responses to priming doses for 20 of 21 antigens. The largest effects were observed for inactivated polio vaccine, where 2-fold higher maternal antibody concentrations resulted in 20% to 28% lower postvaccination antibody concentration (geometric mean ratios [GMRs], type 1: 0.80; 95% CI, 0.78-0.83; type 2: 0.72; 95% CI, 0.69-0.74; type 3: 0.78; 95% CI, 0.75-0.82). For acellular pertussis antigens, 2-fold higher maternal antibody was associated with 11% lower postvaccination antibody for pertussis toxoid (GMR, 0.89; 95% CI, 0.87-0.90) and filamentous hemagglutinin (GMR, 0.89; 95% CI, 0.88-0.90) and 22% lower pertactin antibody (GMR, 0.78; 95% CI, 0.77-0.80). For tetanus and diphtheria, these estimates were 13% (GMR, 0.87; 95% CI, 0.86-0.88) and 24% (GMR, 0.76; 95% CI, 0.74-0.77), respectively. The influence of maternal antibody was still evident in reduced responses to booster doses of acellular pertussis, inactivated polio, and diphtheria vaccines at 12 to 24 months of age. Children who were older when first immunized had higher antibody responses to priming doses for 18 of 21 antigens, after adjusting for the effect of maternal antibody concentrations. The largest effect was seen for polyribosylribitol phosphate antibody, where responses were 71% higher per month (GMR, 1.71; 95% CI, 1.52-1.92). Conclusions and Relevance: Maternal antibody concentrations and infant age at first vaccination both influence infant vaccine responses. These effects are seen for almost all vaccines contained in global immunization programs and influence immune response for some vaccines even at the age of 24 months. These data highlight the potential for maternal immunization strategies to influence established infant programs.
Authors: Elke Leuridan; Niel Hens; Natasja Peeters; Liene de Witte; Olivier Van der Meeren; Pierre Van Damme Journal: Pediatr Infect Dis J Date: 2011-07 Impact factor: 2.129
Authors: Abbey J Hardy-Fairbanks; Stephanie J Pan; Michael D Decker; David R Johnson; David P Greenberg; Kathryn B Kirkland; Elizabeth A Talbot; Henry H Bernstein Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Gayatri Amirthalingam; Nick Andrews; Helen Campbell; Sonia Ribeiro; Edna Kara; Katherine Donegan; Norman K Fry; Elizabeth Miller; Mary Ramsay Journal: Lancet Date: 2014-07-15 Impact factor: 79.321
Authors: Ha Thi Thu Hoang; Elke Leuridan; Kirsten Maertens; Trung Dac Nguyen; Niel Hens; Ngoc Ha Vu; Raissa Nadège Caboré; Hong Thi Duong; Kris Huygen; Pierre Van Damme; Anh Duc Dang Journal: Vaccine Date: 2015-10-31 Impact factor: 3.641
Authors: Alassane Dicko; Olumuyiwa O Odusanya; Abdoulbaki I Diallo; Gaoussou Santara; Amadou Barry; Amagana Dolo; Aminata Diallo; Yetunde A Kuyinu; Omolara A Kehinde; Nancy François; Dorota Borys; Juan P Yarzabal; Marta Moreira; Lode Schuerman Journal: BMC Public Health Date: 2011-11-23 Impact factor: 3.295
Authors: Elinor Willis; Norbert Pardi; Kaela Parkhouse; Barbara L Mui; Ying K Tam; Drew Weissman; Scott E Hensley Journal: Sci Transl Med Date: 2020-01-08 Impact factor: 17.956
Authors: Sylvia Becker-Dreps; Anne M Butler; Leah J McGrath; Kim A Boggess; David J Weber; Dongmei Li; Michael G Hudgens; J Bradley Layton Journal: Am J Prev Med Date: 2018-06-14 Impact factor: 5.043
Authors: Elsbeth D M Rouers; Patricia C J Bruijning-Verhagen; Pieter G M van Gageldonk; Josephine A P van Dongen; Elisabeth A M Sanders; Guy A M Berbers Journal: JAMA Date: 2020-09-15 Impact factor: 56.272